Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
Abstract:
Provided herein are novel 2,7-naphthyridine compounds as MASTL inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Related Concept Videos
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
Drugs that Destabilize Microtubules
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
